Page 125 - FINAL PROGRAMME 2017

TUESDAY, 4 JULY 2017
SELECTED ORAL COMMUNICATIONS
15:15 - 16:30 Room A
Session 48: Outcomes and ovarian stimulation
Chairman: N. Macklon (United Kingdom) Chairman: R. Cabry-Goubet (Switzerland)
15:15 O-171
15:30 O-172
15:45 O-173
16:00 O-174
Ovarian stimulation with Corifollitropin alpha (CFA) for 7 days leads to reduced progesterone levels on the day of trigger and to higher ongoing pregnancy rates
H.M. Fatemi1, I. Missiou2, J. Long3, B. Lawrenz4
1IVI, Middle east, Abu Dhabi, United Arab Emirates
2MSD, EUCAN MSD, Athens, Greece
3Merck Sharp & Dohme Corp., Whitehouse Station, NJ- U.S.A., U.S.A. 4IVI, ART, Abu Dhabi, United Arab Emirates
Time interval between hCG administration and oocyte retrieval signi cantly in uences IVF- ET results
T. Tadros1, L. Chenoz1, M. Poulain1, E. Adda-Herzog1, J.M. Ayoubi1, R. Fanchin1 1Foch Hospital, Reproductive Medicine Unit, Suresnes, France
The negative effect of progesterone levels on hCG administration (Phcg) on live-birth rate (LBR) is not restricted to values above 1.5 ng/ml in IVF/ICSI cycles
P. Arvis1, P. Lehert2, A. Guivarc'h1, F. Jaffre1
1Clinique la Sagesse, AMP, Rennes, France
2Faculty of Medicine-, the University of Melbourne, Melbourne 3010- Victoria-, Australia
Cumulative ongoing pregnancy and live birth rates following repeated controlled ovarian stimulation (COS) cycles using individualised follitropin delta dosing compared to conventional follitropin alfa dosing
J. Havelock1, E. Bosch2, F. Sánchez Martin3, B. Mirner Klein4, B. Mannaerts5, J.C. Arce6, ESTHER-1 and ESTHER-27
1Paci c Centre for Reproductive Medicine, Burnaby- B.C., Canada
2IVI Valencia, Human Reproductive Unit, Valencia, Spain
3Ginemed, Obstetrics and Gynecology Department, Seville, Spain
4Ferring Pharmaceuticals, Global Clinical R&D, Copenhagen, Denmark 5Ferring Pharmaceuticals, TA Reproductive Health, Copenhagen, Denmark 6Ferring Pharmaceuticals, US Development, Parsippany, U.S.A.
7On behalf of the ESTHER-1 and ESTHER-2 trial group, Evidence-based Stimulation Trial with Human rFSH in Europe and Rest of World, Copenhagen, Denmark
FINAL PROGRAMME I GENEVA, SWITZERLAND – 2 TO 5 JULY 2017 125
SCIENTIFIC PROGRAMME TUESDAY, 4 JULY